Director Keith Murphy filed a Form 4 with the SEC on November 6, 2026, disclosing the grant of a stock option to purchase 5,000 shares of Matinas BioPharma Holdings, Inc. common stock under the company's 2025 Equity Incentive Plan.

Key Highlights

  • Reporting person: Keith Murphy, identified as a Director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB)
  • Transaction date: November 6, 2026, the grant date of the stock option
  • Shares covered: 5,000 shares of common stock, par value $0.0001 per share
  • Exercise price: $1.16 per share, with an expiration date of November 6, 2036
  • Price paid for the option: $0, as reported in the filing
  • Vesting terms: The option vests in full on the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the 2025 Equity Incentive Plan, subject to continued service
  • Post-transaction derivative holdings: 5,000 derivative securities beneficially owned following the reported transaction, held directly

Director Option Grant Details for Keith Murphy at Matinas BioPharma

According to the Form 4 filed with the SEC on November 6, 2026, director Keith Murphy was granted a stock option to purchase 5,000 shares of Matinas BioPharma Holdings, Inc. common stock at an exercise price of $1.16 per share. The filing reports the transaction code as "A" (acquired) and states that the price paid for the derivative security was $0. The option is classified as a "Stock Option (right to Buy)" under Table II of the filing, covering derivative securities.

The filing discloses that the option was granted pursuant to the Issuer's 2025 Equity Incentive Plan. Per the explanation of responses, the option "will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a 'Change in Control' (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date." The expiration date of the option is November 6, 2036, giving it a ten-year term from the grant date.

The Form 4 was signed by Jerome D. Jabbour as attorney-in-fact for Keith Murphy, also dated November 6, 2026. No shares of non-derivative common stock were reported as acquired or disposed of in Table I of the filing. Following the reported transaction, Murphy's beneficial ownership of derivative securities stands at 5,000, held directly, according to the filing.

What Was Disclosed

Matinas BioPharma Holdings, Inc. director Keith Murphy disclosed receipt of a stock option for 5,000 shares at $1.16 per share, granted November 6, 2026, under the company's 2025 Equity Incentive Plan, with cliff vesting after one year or upon a Change in Control.